Prognostic significance of AMPK activation in advanced stage colorectal cancer treated with chemotherapy plus bevacizumab

Elisabetta Zulato, Vittorina Zagonel(Istituto Oncologico Veneto)

British Journal of Cancer

June 3, 2014

10.1038/bjc.2014.274

Cited by 48

Related Papers

Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer

|New England Journal of Medicine|2014|1.1k

Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial

|The Lancet Oncology|2016|1k

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

|The Lancet Oncology|2020|322

Assessment of a HER2 scoring system for colorectal cancer: results from a validation study

|Modern Pathology|2015|317

Nutritional Support in Cancer Patients: A Position Paper from the Italian Society of Medical Oncology (AIOM) and the Italian Society of Artificial Nutrition and Metabolism (SINPE)

|Journal of Cancer|2015|144